AVBP · XBRL financial data
ArriVent BioPharma financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (AVBP's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Research and development | 79,004 | 153,351 |
| General and administrative | 15,304 | 24,183 |
| Total operating expenses | 94,308 | 177,534 |
| Operating income (loss) | (94,308) | (177,534) |
| Net income (loss) | (80,488) | (166,308) |
| Earnings per share, basic USD per share | (2.56) | (4.32) |
| Earnings per share, diluted USD per share | (2.56) | (4.32) |
| Weighted average shares, basic thousands of shares | 31,469 | 38,463 |
| Weighted average shares, diluted thousands of shares | 31,469 | 38,463 |
Balance sheet
CSVFiscal years (AVBP's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 74,293 | 45,540 |
| Short-term investments | 144,570 | 267,281 |
| Prepaid and other current assets | 8,116 | 20,076 |
| Total current assets | 226,979 | 332,897 |
| Right-of-use asset | 154 | 13 |
| Total assets | 274,942 | 333,169 |
| Accounts payable | 3,782 | 5,934 |
| Accrued liabilities | 13,330 | 19,997 |
| Total current liabilities | 17,274 | 25,945 |
| Lease liability, non-current | 14 | — |
| Total liabilities | 17,288 | 25,945 |
| Accumulated deficit | (238,333) | (404,641) |
| Total stockholders' equity | 257,654 | 307,224 |
| Total liabilities and equity | 274,942 | 333,169 |
| Common shares outstanding (cover page) thousands of shares | 34,016 | 44,202 |
Cash flows
CSVFiscal years (AVBP's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (80,488) | (166,308) |
| Stock-based compensation | 3,208 | 12,520 |
| Net cash from operating activities | (70,212) | (160,588) |
| Net cash from investing activities | (192,465) | (71,228) |
| Proceeds from issuing common stock | 185,950 | 202,631 |
| Net cash from financing activities | 186,581 | 203,063 |
| Net change in cash | (76,096) | (28,753) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| ArriVent BioPharma | 154,682 | not reported | (39,581)* | 49.3M | 9.4 quarters | 10-QJun 30, 2026 |
| Phibro Animal Health | 75,548 | 386,774 | 26,082 | not reported | — | 10-QSep 30, 2026 |
| uniQure | 98,442 | 5,196 | (47,827)* | 70.1M | 2.6 quarters | 10-QSep 30, 2026 |
| Pacira BioSciences | 246,957 | 176,653 | 50,070* | 40.1M | — | 10-QSep 30, 2026 |
| Cogent Biosciences | 217,461 | not reported | (80,787)* | 174.0M | 9.7 quarters | 10-QSep 30, 2026 |
| Immunome | 217,706 | 0 | (61,692)* | 113.6M | 8.4 quarters | 10-QJun 30, 2026 |
| Syndax Pharmaceuticals | 135,941 | 83,298 | (27,254)* | not reported | 11.9 quarters | 10-QSep 30, 2026 |
| Nurix Therapeutics | 720,242 | 673,064 | 615,631* | 109.2M | — | 10-QAug 31, 2026 |
| Niagen Bioscience | 69,509 | 27,192 | 2,625* | 79.2M | — | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.